BMY

Bristol-Myers Squibb Company

59.56 USD

Last updated Oct 9, 05:09 UTC

Yesterday HIGH

$60.1

Yesterday LOW

$59.01

52w HIGH

$68.64

52w LOW

$42.52

EPS

2.04

PE

29.19

Next Earnings

Oct 29, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Bristol-Myers Squibb Company stock is down -7.54% since 30 days ago. The next earnings date is Oct 29, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54% of the previous 49 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 25% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

08 Oct 15:07	17 Jun, 2027	67.50	CALL	80	921
08 Oct 16:38	19 Mar, 2027	70.00	PUT	20	2087
08 Oct 16:39	19 Mar, 2027	70.00	PUT	20	2087
08 Oct 16:53	30 Oct, 2026	60.00	PUT	100	327
08 Oct 16:56	19 Mar, 2027	60.00	PUT	252	6407
08 Oct 17:20	16 Oct, 2026	57.50	PUT	1078	1775
08 Oct 18:24	23 Oct, 2026	62.00	CALL	1271	2104
08 Oct 18:47	20 Nov, 2026	65.00	CALL	534	14004
08 Oct 19:21	17 Dec, 2027	62.50	PUT	61	230
08 Oct 19:22	17 Dec, 2027	62.50	PUT	58	230

Advanced Data Unlock

Vandana Singh

Fri Sep 4, 2026

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
Benzinga Insights

Wed Sep 2, 2026

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga Newsdesk

Mon Aug 31, 2026

Reported Earlier, Bristol Myers Reports Long-Term Camzyos Data Supporting Continued Use In Obstructive HCM

Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in
Benzinga Newsdesk

Tue Aug 25, 2026

Bristol Myers Spokesperson Says Confirm That We Have Ended Our Partnership With Cellares; Determined Cellares-Partnered Cell Shuttle System Could Not Meet Necessary Requirements To Make Commercial Breyanzi

- Reuters
Avi Kapoor

Tue Aug 25, 2026

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Vandana Singh

Fri Aug 14, 2026

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
Benzinga Newsdesk

Thu Aug 13, 2026

Bristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple Myeloma

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumabandhyaluronidase-fihj and dexamethasone (ZDd) for the
Benzinga Newsdesk

Thu Aug 13, 2026

Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid

In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the
Benzinga Newsdesk

Thu Aug 13, 2026

Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology Indication
Snigdha Gairola

Thu Aug 13, 2026

Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.

Cantor Fitzgerald

Thu Oct 8, 12:41

hold

confirm
Leerink Partners

Mon Oct 5, 15:03

hold

downgrade
Piper Sandler

Wed Sep 16, 19:23

buy

confirm
HSBC

Thu Sep 10, 15:58

hold

confirm

Advanced Data Unlock

Cari Gallman, EVP

Fri Oct 2, 2026

BMY Recent Insider Trades and Stock Chart

9,118 shares converted
Phyllis R Yale, Director

Wed Sep 30, 2026

BMY Recent Insider Trades and Stock Chart

560.9 shares awarded
Theodore R. Samuels, Director

Wed Sep 30, 2026

BMY Recent Insider Trades and Stock Chart

821.31 shares awarded
Derica W Rice, Director

Wed Sep 30, 2026

BMY Recent Insider Trades and Stock Chart

620.99 shares awarded
Michael R McMullen, Director

Wed Sep 30, 2026

BMY Recent Insider Trades and Stock Chart

560.9 shares awarded
Peter J Arduini, Director

Wed Sep 30, 2026

BMY Recent Insider Trades and Stock Chart

560.9 shares awarded
Cristian Massacesi, EVP,Chief Med Offr,Head Dev

Wed Sep 9, 2026

BMY Recent Insider Trades and Stock Chart

6,249 shares sold